Welcome to our dedicated page for Merck & Co SEC filings (Ticker: MRK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Merck & Co., Inc. (NYSE: MRK) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, along with AI-powered summaries to help interpret complex documents. Merck is a New Jersey–incorporated biopharmaceutical preparation manufacturer whose common stock and multiple series of notes are registered on the New York Stock Exchange, as reflected in its Form 8-K filings.
Through this page, readers can review Merck’s current and historical filings, including Form 8-K reports on material events such as public offerings of long-dated notes under its automatic shelf registration statement on Form S-3ASR and announcements of restructuring programs. Filings related to quarterly and annual results, such as earnings releases furnished on Form 8-K, give additional context on the company’s financial condition and performance.
For a research-intensive company like Merck, core SEC filings such as annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) are key sources for information on its human health and animal health businesses, major products like KEYTRUDA and GARDASIL, pipeline programs including WINREVAIR and Alzheimer’s disease candidates, risk factors and capital structure. Forms 3, 4 and 5, when filed, provide details on insider transactions by directors and officers.
Stock Titan enhances these filings with AI-generated explanations that highlight important sections, clarify technical language and point out items that may interest investors, such as new debt issuances, restructuring charges or significant acquisitions. Real-time updates from EDGAR help ensure that newly filed Merck documents, including 10-Ks, 10-Qs and Form 4 insider reports, appear promptly, allowing users to track regulatory disclosures related to MRK in a single, organized feed.
Merck & Co., Inc. executive Richard R. DeLuca, EVP and President of Merck Animal Health, reported routine equity compensation activity. On April 29, 2026, he exercised 2,518 restricted stock units, receiving an equivalent number of Merck common shares.
To cover tax obligations, 1,241 common shares were disposed of at $110.03 per share through a tax-withholding transaction, leaving a net increase in his directly held stock. After these transactions, DeLuca directly holds 161,537.07 shares of common stock and indirectly holds 1,320.9907 shares through a 401(k) plan. Footnotes note that restricted stock units convert into one common share each and vest in three equal installments on April 29, 2026, 2027, and 2028, with remaining units outstanding.
Merck & Co., Inc. executive David Michael Williams reported routine equity compensation activity involving restricted stock units and related tax withholding. He exercised 1,377 restricted stock units into the same number of common shares at a stated value of $110.03 per share and 679 common shares were disposed of to cover tax obligations.
Following these transactions, he directly held 31,716.037 shares of Merck common stock. He also held 2,755 restricted stock units, each representing a contingent right to receive one Merck common share, which are scheduled to vest and be distributed in three equal installments on April 29, 2026, April 29, 2027 and April 29, 2028. Holdings include shares acquired through dividend reinvestment.
Merck & Co., Inc. senior vice president Dalton E. Smart III reported routine equity compensation activity. On April 29–30, 2026, he exercised restricted stock units covering 1,408 shares of common stock, converting them into directly held shares.
Across these transactions, 483 shares of common stock were withheld at prices of $110.03 and $110.95 per share to satisfy tax obligations, so they were not open-market sales. Following the transactions, he directly holds 9,137.315 shares of Merck common stock.
Footnotes show he also holds 1,889 restricted stock units, each representing a contingent right to one share of Merck common stock. These units vest and are distributed in three equal installments on 4/29/2026, 4/29/2027, 4/29/2028, and on 4/30/2025, 4/30/2026, and 4/30/2027.
Merck & Co., Inc. Executive VP & President, MRL, Dean Y. Li exercised restricted stock units and settled related taxes in shares. On April 29, 2026, 4,722 restricted stock units converted into the same number of common shares, while 2,326 shares were withheld to cover tax obligations at $110.03 per share.
After these transactions, Li directly owned 96,757.05 shares of Merck common stock and held 9,444 restricted stock units outstanding. The RSUs vest and are distributed in three equal installments on April 29, 2026, April 29, 2027, and April 29, 2028.
Merck & Co., Inc. EVP and General Counsel Jennifer Zachary reported compensation-related equity transactions. On 4/29/2026, she exercised 2,951 restricted stock units into an equal number of Merck common shares. In a related move, 1,454 common shares were disposed of to cover tax obligations.
Following the derivative exercise, one transaction line shows 72,351.254 common shares owned directly, while another reflects 70,897.254 shares after the tax-withholding disposition. Footnotes explain that each restricted stock unit represents a contingent right to one Merck share and that these units vest in three equal installments on 4/29/2026, 4/29/2027, and 4/29/2028.
Merck & Co., Inc. executive vice president and Chief HR Officer Betty D. Larson reported routine equity compensation activity over two days. She exercised restricted stock units to acquire 13,435 shares of common stock at reference prices of $110.95 and $110.03 per share, and 5,858 shares were disposed of to cover tax obligations through share withholding rather than open-market sales.
Following these transactions, Larson directly owned 18,917 shares of Merck common stock. The filing reflects compensation-related derivative exercises and associated tax-withholding dispositions, without any open-market buying or selling.
Merck & Co., Inc. Executive Vice President and CFO Caroline Litchfield reported routine equity compensation activity. She exercised 3,935 restricted stock units, converting them into the same number of common shares at a stated value of $110.03 per share. To cover tax obligations, 1,938 common shares were disposed of in a tax-withholding transaction, rather than an open-market sale. After these transactions, she directly holds about 94,238.657 common shares and 7,870 restricted stock units that continue to vest over time. Footnotes indicate her holdings also include shares acquired through dividend reinvestment.
Merck & Co., Inc. Chairman, CEO & President Robert M. Davis reported routine equity compensation activity. On 4/29/2026, he exercised 13,300 restricted stock units into common shares at a reported value of $110.03 per share, while 6,551 shares were withheld to cover tax obligations. Following these transactions, he directly held about 450,350.757 shares of Merck common stock and 26,601 restricted stock units. The remaining restricted stock units vest and are distributed in equal installments on 4/29/2027 and 4/29/2028.
Merck & Co., Inc. executive vice president for Oncology & International, Johannes Jacobus Oosthuizen, reported routine equity compensation activity. He exercised 1,377 Restricted Stock Units (RSUs), converting them into the same number of Merck common shares at a reported value of $110.03 per share. To cover tax obligations, 679 common shares were disposed of through a tax-withholding transaction rather than an open-market sale. Following these transactions, Oosthuizen directly holds about 21,895.389 common shares. Footnotes state that each RSU represents a contingent right to one share of common stock and that the RSUs vest in three equal installments on 4/29/2026, 4/29/2027, and 4/29/2028, highlighting that this event is part of an ongoing vesting schedule.
Merck & Co Inc: Vanguard Capital Management reports beneficial ownership of 186,323,766 shares of Common Stock, representing 7.53% of the class. The filing shows sole voting power for 25,336,142 shares and sole dispositive power for 186,323,766 shares. The report is signed on 04/30/2026 and describes holdings exercised by Vanguard Capital Management LLC and specified affiliates under SEC Release No. 34-39538.